01 January 2008
Cyclosporine use in miscellaneous clinical settings other than organ transplantations: Is there any evidence for target levels?
Hundie Tesfaye, Richard Prusa, Blanka Jedlickova, Jitka SegethovaAnn Transplant 2008; 13(4): 34-40 :: ID: 880216
Abstract
Background: Cyclosporine, once a corner stone in organ transplantation for decades, its use is expanded to treat several autoimmune conditions despite lacking profound evidence for its advantages. The aim of the retrospective study was to evaluate differences in trough blood levels of cyclosporine in some clinical indications other than transplantation.
Material/Methods: Blood cyclosporine trough levels determined by fluorescent polarization immunoassay (FPIA) TDx Abbott Diagnostics for TDM purpose in one year period was pooled from laboratory data-base. Total of 304 levels from 45 patients (26 males: 19 females) aged 2-62 years, who were on oral cyclosporine daily maintenance dose for conditions like systemic lupus erythematosus (SLE), atopic dermatitis (ADS), idiopathic thrombocytopenic purpura (ITP), dermatopolymyositis (DMS), and cardiomyopathy (CMP) were included.
Results: Cyclosporine trough was undetectable in 27 occasions, with maximum1213 μg/L, mode 74 ug/L, median 91 ug/L, mean 104.4±119.5 ug/L SD, and SE 6.85 respectively. Despite poorly defined target, most clinicians desired trough concentrations not exceeding 100 μg/L, aiming to reduce toxicity. In this respect, nearly 35% were above this point, whereas 8% were below the detection limit of the method. There were no significant differences in concentrations within diagnostic groups except for ADS versus ITP (p<0.0039).
Conclusions: Extended use of cyclosporine in several autoimmune diseases is promising. However, no evidence-based target levels in miscellaneous indications. Studies are needed to demonstrate overall benefits of CSA in relation to trough level and dynamic indicators (biomarkers) like expression of IL-2 and its receptor as targeted cell products in the future.
Keywords: hla class I, Cyclosporine, therapeutic use, granuloma annulare, localized, tacrolimus, calcineurin inhibitors
In Press
18 Mar 2024 : Original article
Does Antibiotic Use Increase the Risk of Post-Transplantation Diabetes Mellitus? A Retrospective Study of R...Ann Transplant In Press; DOI: 10.12659/AOT.943282
20 Mar 2024 : Original article
Transplant Nephrectomy: A Comparative Study of Timing and Techniques in a Single InstitutionAnn Transplant In Press; DOI: 10.12659/AOT.942252
28 Mar 2024 : Original article
Association Between FEV₁ Decline Rate and Mortality in Long-Term Follow-Up of a 21-Patient Pilot Clinical T...Ann Transplant In Press; DOI: 10.12659/AOT.942823
02 Apr 2024 : Original article
Liver Transplantation from Brain-Dead Donors with Hepatitis B or C in South Korea: A 2014-2020 Korean Organ...Ann Transplant In Press; DOI: 10.12659/AOT.943588
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860